Triggering receptor expressed in myeloid cells (TREM)2 is a genetic high-risk factor for sporadic Alzheimer's disease (AD) and is considered a potential target for AD diagnosis and therapy, although its role in the different stages of AD remains controversial. We generated an embryonic deletion of Trem2 (whole body deletion) and induced hippocampal-and cortical-specific knockdown of microglial Trem2 at different stages of the AD process in amyloid precursor protein/Psen1 mice by adeno-associated virus (AAV) infection. AAV infection induced microglial Trem2 overexpression in the hippocampus of wild-type (WT) and thymus cell antigen 1-enhanced green fluorescent protein mice. Mice were subjected to ethological and pathologic tests. Whole body genetic deletion of Trem2 exerted different electrophysiological outcomes between different AD pathologic stages, which results from a complex integration of synaptic loss and amyloid aggregation. Interestingly, knockdown of Trem2 at the early-middle stage of AD (2-6 mo) prevents synaptic loss through directly inhibiting microglial phagocytosis, whereas knockdown of Trem2 at the middle-late stage of AD (6-10 mo) accelerates synaptic dysfunction because of more severe amyloid deposition caused by the depression of microglial phagocytosis. Additionally, hippocampal overexpression of Trem2 in WT mice results in significant synaptic impairment. Here, with transgenic technology and electrophysiological assay, we revealed that TREM2 up-regulation promotes microglial phagocytosis equally against synapse and amyloid plaques and eventually results in different outcomes. During the early-middle pathologic stage, TREM2 enhancing microglial phagocytosis mainly causes synaptic loss. However, TREM2 up-regulating microglial phagocytosis gradually supports a positive role when amyloid deposition occupies the leading position at the middle-late pathologic stage. In this study, we highlighted that TREM2 triggers synaptic loss during AD pathology development
pathologic development of AD (1) (2) (3) . AD is the most common cause of dementia in the elderly and has become the sixth leading cause of death in the United States.
No successful drug has been developed to treat AD (4), but basic research to explore the pathology of AD is ongoing and aims to identify suitable drug targets and therapeutic methods. Whole-genome sequencing studies have provided critical insight into AD by identifying a series of risk genes, including triggering receptor expressed in myeloid cells (TREM)2 (5, 6) . Rare mutations in Trem2 (7) (8) (9) (10) , such as the most common, R47H (substitution of Arg with His at aa 47) (7, 8) , significantly increase the risk of developing AD.
TREM2, a transmembrane protein harboring a V-type Ig domain, is expressed in microglia, osteoclasts, and alveolar macrophages (11) . TREM2 has multiple ligands, including lipids (e.g., phospholipids) and apolipoproteins (Apo) (e.g., ApoE, ApoA1, ApoB, and HDL and LDL) (10, 12) . In microglia, upon binding to its ligand, TREM2 interacts with DAP12 (DNAX activation protein 12) and induces its phosphorylation to recruit spleen tyrosine kinase. The activation of spleen tyrosine kinase initiates intracellular Ca 2+ mobilization and provokes PI3K and MAPK (11) . These signaling cascades eventually activate TREM2 in microglia, where it implements functions including regulation of phagocytosis (13) (14) (15) . Phagocytosis of microglia in AD related to A-b and synaptic plasticity has become a research hotspot (16) . TREM2-induced microglial phagocytosis, which engulfs and clears debris (15) , A-b (12) , and other materials (such as bacteria) (17) , helps maintain tissue homeostasis, although chronic activation of microglia removes synaptic elements and induces the proinflammatory state, which is correlated with severe neurodegeneration (18) . The complex effects of microglia induced by TREM2 require further investigation to understand the role that TREM2 plays in AD progression and for the development of novel therapeutics based on TREM2 and microglia. TREM2-induced phagocytosis may be a mechanism to remove pathogenic A-b or apoptotic cells and is thus closely related to AD pathogenesis.
Loss of TREM2 function elevates the risk of developing AD because Trem2 mutations, such as Q33X, T66M, Y38C, R47H, and R62H, reduce TREM2 function, expression, or signaling, which are closely linked to AD pathogenesis (7, 10, (19) (20) (21) . Two Trem2 mutations, D87N and T96K, induce higher TREM2 activity and may enhance the risk of AD (10) . Enhanced and impaired TREM2 activity and signaling or altered TREM2 homeostasis may lead to serious consequences, thereby promoting AD development. Several clinical and animal studies have shown elevated levels of TREM2 in the brains of patients with AD and mouse models with A-b deposition (22) (23) (24) (25) , suggesting hyperactivation of TREM2 in AD pathology. However, it is unknown whether nongenetic overactivation of TREM2 promotes AD development and its underlying mechanism.
To obtain additional details about the role of TREM2 in AD progression, we spontaneously deleted Trem2 in amyloid precursor protein/Psen1 (APP/PS1) mice during different stages of AD progression. Microglial Trem2 deletion during the early-middle stage of AD successfully prevented AD symptoms, such as synaptic dysfunction and cognitive decline, but pathologic symptoms were exacerbated after microglial Trem2 deficiency during middle-late stage. These results indicate that TREM2 functions during the early stage of AD and plays a crucial role, eventually leading to severe AD pathology. Cg-Tg (Thy1-EGFP) OJrs/GfngJ] from a C57BL/6 background were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Male mice exclusively were used for all experiments. To breed systematic Trem2 knockout (KO) mice, Trem2 fl/fl mice were crossed with CMV-cre mice to generate Trem2 +/2 mice (Trem2 fl/+ , CMV-cre). Trem2 +/2 mice were backcrossed with wild-type (WT, C57BL/6) mice to remove CMV-cre. Trem2 KO mice were crossed with APP/PS1 mice to generate APP/ PS1-Trem2 KO mice. Trem2 fl/fl mice were crossed with APP/ PS1 mice to produce APP/PS1-Trem2 fl/fl mice. All animal procedures were approved by the Administration Committee of Experimental Animals, Jiangsu Province, and Nanjing Medical University. Animals were fed standard mouse chow and water ad libitum and were housed in a temperature-and humidity-controlled environment under a 12-h light/dark cycle.
MATERIALS AND METHODS

Mice
Quantitative RT-PCR
Total RNA in brain tissues was extracted using Trizol reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. Equal amounts of total RNA were reverse transcribed under standard conditions using the Prime-ScriptTM Reverse Transcription Reagent Kit (Takara Bio, Tokyo, Japan). PCR was performed using the StepOnePlus System (Thermo Fisher Scientific) with Sybr Premix Ex Taq II (Takara Bio) and the appropriate primers (Trem2: forward 59-CTG-GAACCGTCACCATCACTC-39, reverse 59-CGAAACTCGATG-ACTCCTCGG-39; glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward 59-AGGTCGGTGTGAACGGATTTG-39, reverse 59-GGGGTCGTTGATGGCAACA-39). GAPDH was used as the internal control.
Western blot analysis
Brain tissues were lysed with lysis buffer (Beyotime, Nanjing, China). The resulting proteins were separated on SDS polyacrylamide gels, transferred to PVDF membranes (MilliporeSigma, Burlington, MA, USA), and blocked with 5% bovine serum albumin (BSA). Membranes were incubated with primary antibodies against TREM2 (1:400, 91068; Cell Signaling Technology, Danvers, MA, USA), synaptophysin (1:1000, ab14692; Abcam, Cambridge, United Kingdom), postsynaptic density 95 (PSD95, 1:1000, ab13552; Abcam), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor A (GluA) 1 (1:1000, 13185; Cell Signaling Technology), GluA2 (1:1000, 13607; Cell Signaling Technology), GluA3 (1:1000, 5117; Cell Signaling Technology), GluA4 (1:1000, ab171423; Abcam), NMDA receptor (GluN) 1 (1:1000, 5704; Cell Signaling Technology), GluN2a (1:1000, 4205; Cell Signaling Technology), GluN2b (1:1000, 14544; Cell Signaling Technology), CD33 (1:1000, ab134115; Abcam), lysosome-associated membrane glycoprotein 1 (LAMP1, 1:1000, 3243; Cell Signaling Technology), and b-actin (1:500, 47778; Santa Cruz Biotechnology, Dallas, TX, USA). The membranes were then washed 3 times and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody. Protein bands were detected with the Immobilon Western Chemiluminescent horseradish peroxidase substrate (MilliporeSigma) and analyzed using Quantity One software (Bio-Rad, Hercules, CA, USA).
Electrophysiological assay
A 250-mm transverse slice of the hippocampus was prepared from freshly removed mouse brain using the Leica VT1200 Vibratome (Leica Microsystems, Wetzlar, Germany) in an ice-cold bath (;4°C). The slice was maintained at room temperature in a humidified, bubbled interface chamber containing artificial cerebrospinal fluid (ACSF; including 124 mM NaCl, 1.25 mM KH 2 PO 4 , 2.69 mM KCl, 2 mM MgSO 4 , 2 mM CaCl 2 , 26 mM NaHCO 3 , and 10 mM glucose) for ;2.5 h and then transferred to a submerged recording chamber that was constantly perfused with oxygenated ACSF containing 50 mM bicuculline methobromide (Tocris Bioscience, Bristol, United Kingdom) at 32-34°C. The field excitatory postsynaptic potential (fEPSP) of the CA3-CA1 circuits was recorded by stimulating and recording the electrodes positioned within the stratum radiatum near the CA3 region and in the CA1 region. The fEPSPs were recorded using ACSF-filled glass pipettes (2-3 MV), amplified using the Axopatch 2B amplifier (Molecular Devices, Sunnyvale, CA, USA), and recorded using Clampex 9 software (Molecular Devices). Stimuli (100 ms) were delivered through a concentric bipolar electrode [TM53CCINS; World Precision Instruments (WPI), Sarasota, FL, USA]. Four individual traces were averaged for each data point. The same intensity was used during the baseline recording (0.067 Hz). Long-term potentiation (LTP) was induced by 100 stimuli at 100 Hz (1 s). The LTP level was determined based on the mean fEPSP initial slope from 30 to 60 min after the tetanus. Data were analyzed and processed using Clampfit 9 and Microsoft Excel (Microsoft, Redmond, WA, USA).
For spontaneous excitatory postsynaptic current (sEPSC) recording from CA1 pyramidal neuron, the hippocampal slice was cut as previously described, placed in the recording chamber, and constantly perfused with oxygenated ACSF. CA1 pyramidal neuron was selected under an upright microscope equipped with a 340 water-immersion lens (Axioskop 2 Plus; Carl Zeiss, Oberkochen, Germany) and whole-cell patch-clamp was recorded by MultiClamp 700B Amplifier and 1440A Digitizer (Molecular Devices). In detail, we filled a micropipette with solution containing (in millimolars) 1 MgCl 2 , 0.2 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 125 cesium methanesulfonate, 5 CsCl, 10 phosphocreatine, and 5 QX314 (pH 7.4, 285 mOsm) and held pyramidal neuron at 270 mV in the presence of 20 mM body mass index (MilliporeSigma). Additionally, miniature excitatory postsynaptic current (mEPSC) was recorded similar to sEPSC but in the presence of 1 mm tetrodotoxin.
Immunofluorescence
Mice were anesthetized with ketamine, perfused with ice-cold PBS, and fixed in 4% paraformaldehyde overnight (26) . Sucrose (20 and 30%) was used for brain dehydration. Brains were frozen and cut on a freezing sliding microtome (CM1950; Leica Microsystems). Serial 10-mm coronal sections were collected from the rostral anterior commissure to the caudal hippocampus. Brain sections were permeabilized in PBS containing 0.3% Triton X-100 prior to blocking in 10% goat serum in 13 PBS at room temperature for 1 h. Sections were incubated with the following primary antibodies overnight at 4°C: anti-vesicular glutamate transporter 1 (vGlut1) (Atto 488 labeled, 1:500, N1602-At488; Synaptic Systems, Goettingen, Germany), anti-6E10 (1:5000, SIG-39320; Covance, Princeton, NJ, USA), anti-ionized calcium binding adaptor molecule 1 (Iba1) (1:300, 019-19741; Wako BioProducts, Richmond, VA, USA), and anti-CD68 (1:800, 76437S; Cell Signaling Technology). After rinsing 3 times, sections were incubated with the appropriate Alexa Fluor-conjugated secondary antibodies [goat anti-rabbit Alexa Fluor 488 (1:500, A-11034), goat anti-mouse Alexa Fluor 488 (1:500, A-11001), goat anti-mouse Alexa Fluor 633 (1:500, A-21046), or goat anti-rabbit Alexa Fluor 633 (1:500, A-21086; all from Thermo Fisher Scientific)] for 1 h at room temperature. Images were obtained using the Olympus FV1000 confocal laser scanning microscope (Olympus, Tokyo, Japan) and processed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). For synaptic analyses, images were captured in burst mode at a step size of 0.6 mm, and composite images were created using Olympus FV10 ASW (v.4.1; Olympus). For vGlut1 puncta, the number of Iba1-positive cells, plaque-related Iba1-positive cells (20 mm from the center of adjacent amyloid plaque), and amyloid plaques were measured.
Golgi staining
In brief, brain samples were fixed with 4% paraformaldehyde overnight at 4°C immediately after removing from anesthetized mice and then immersed by 3% potassium bichromate for 3 d and 2% silver nitrate solution for 24 h in the dark, sequentially. After that, frozen sections of brain samples were prepared at 100 mm by cryostat microtome and dehydrated by 95 and 100% ethanol, cleared in xylene, and sealed with antifade mounting medium (Beyotime). The brain sections were observed under Olympus FV1000 confocal laser scanning microscope, and spine analysis was performed by Olympus FV10 ASW (v.4.1) layer by layer with a step size of 0.4 mm per layer along the z axis. After that, we rebuilt the 3-dimensional structure using FV10 ASW software. For dendritic morphologic analyses, 200-mm primary dendritic segments from the cell body were traced, and the full length of secondary dendritic segments and calculated spine density and number of different spine shapes (thin, diameter of the head is much smaller than the diameter of the neck; mushroom, diameter of the head is similar to the diameter of the neck; and stubby, diameter of the head is much greater than the diameter of the neck) were calculated as previously described by Harris et al. (27) .
Morris water maze test
The Morris water maze (MWM) test was performed in a double-blind manner during the last 8 d prior to euthanasia. A white-colored plastic pool with a 120-cm diameter was filled with water. The water temperature was maintained at 20 6 1°C using a bath heater. In the visible platform training and test (d 1 and 2), a 7-cm white cylindrical platform was placed 0.5 cm above the water surface, and mice were placed in different quadrants in order to test nonspatial training and learning (the test session was 2 h apart from the previous session). In the hidden platform training and test (d 3-7), the platform was moved to the opposite quadrant, and the mice were placed in different quadrants in order to test spatial training and learning (the test session was 2 h apart from the previous session). In the visible platform and hidden platform test, if mice did not find the platform in 60 s, they were led to the platform and kept there for 3 s to reinforce memory of the location, and the swimming paths were recorded on a computer (Any-maze; Global Biotech, Mount Laurel, NJ, USA). The mean swimming speed (meters/s) and time (s) required to reach the visible or hidden platform were calculated for each mouse. On d 8 (transfer test), we removed the platform and placed mice in the quadrant opposite to the target quadrant (where the platform was previously). On d 8, the time spent in each quadrant was evaluated.
Synaptosome collection
Hippocampi were separated from 20 mice per group, homogenized with 15 ml prepared buffer (0.1 mM CaCl 2 , 1 mM MaCl 2 , 0.32 M sucrose, and 0.1 mM PMSF), and then placed on ice, based on a previously published study (28) . Then, we adjusted the sucrose concentration of homogenate to 1.25 M with 70 ml 2 M sucrose and 30 ml 0.1 mM CaCl 2 and evenly transferred it to 6 ultracentrifuge tubes. After overlaying 10 ml 1 M sucrose buffer (1 M sucrose and 0.1 mM CaCl 2 ) and centrifuging under 100,000 g at 4°C for 3 h, we collected the synaptosomal membranes representing at the 1.25/1.0 M sucrose interface.
Presynaptic and postsynaptic element isolation
Four milliliters of extracted synaptosomes was diluted 10 times with 36 ml cold 0.1 mM CaCl 2 and buffered with an equal volume (40 ml) of isolation buffer (40 mM Tris and 2% Triton X-100), and we adjusted the mixture's pH to 6.0 for presynaptic proteins or to 8.0 for postsynaptic proteins. After incubation on ice for 20 min, the mixture was centrifuged at 10,000 g at 4°C for 30 min, and pellets were collected. Two hundred microliters 0.1 mM CaCl 2 was used to suspend the pellets, and an additional 200 ml 23 SDS-PAGE was further assayeded for Western blot (WB) assay.
ELISA
Brain tissues were homogenized with lysis buffer on ice and centrifuged at 4°C at 12,000 rpm for 10 min to remove cell debris. The supernatants were collected to determine the levels of A-b40, A-b42, and total protein. The A-b40 and A-b42 levels were determined by ELISA kits (Thermo Fisher Scientific) according to the manufacturer's instructions.
Secretase and cathepsin activity assay
Similar to ELISA, we homogenized brain tissues and collected supernatants. Secretase activity was detected by a-Secretase Activity Kit and g-Secretase Activity Kit, and capthepsin activity was detected by a Cathepsin B Activity Kit and a Cathepsin E Activity Kit according to the manufacturer's instructions (Biovision, San Francisco, CA, USA). Fluorescence intensity was evaluated by Safire2 Microplate Reader (Tecan, Männedorf, Switzerland).
Magnetic-activated cell sorting
Hippocampi from 6 mice per group were isolated, minced on ice, and digested in Hank's Balanced Salt Solution (Thermo Fisher Scientific) containing 300 mg/ml DNasel (MilliporeSigma) and 0.125% trypsin at 37°C for 30 min. Then, we centrifuged the cell suspension at 300 g for 10 min and collected cell pellets. According to the manufacturer's instructions of CD11b MicroBeads Kit (Miltenyi Biotech, Bergisch Gladbach, Germany), we suspended cell pellets with working buffer and incubated them with CD11b MicroBeads. After that, we applied cell suspension onto the LS column (placed in the magnetic field) and washed with separation buffer to remove unlabeled cells. Then, we removed the column from the separator, pipetted the appropriate amount of buffer into the column, and collected microglia.
Flow cytometry assay
The purity of microglia isolated from magnetic-activated cell sorting was further evaluated by flow cytometry assay. In detail, we diluted isolated microglia with PBS (containing 5% BSA), and centrifuged it at 300 g for 10 min. After resuspending with PBS (containing 5% BSA), the microglia were stained directly with FITC rat anti-mouse CD45 (BD Biosciences, San Jose, CA, USA) and allophycocyanin rat anti-mouse CD11b (BD Biosciences), consequently. Then cells were washed with PBS (containing 0.05% BSA) twice and examined by flow cytometry (BD Biosciences). Data were analyzed by FlowJo software (BD Biosciences).
Isolated microglia culture
After isolation, microglial cells were plated in 60-mm 2 poly-Llysine-coated dishes at ;0.3 3 105 cells/mm in DMEM/F12 (1:1) medium supplemented with insulin, 10% fetal bovine serum, L-glutamine, and gentamicin.
Fluorescently labeled A-b1-42 preparation
Fluorescently labeled A-b1-42 fibrils (FLfA-b42) were prepared prior to microglial phagocytosis. The synthetic A-b1-42 peptide was aged at 37°C for 1 wk, and the samples were labeled with Alexa Fluor 488 dye at 4°C overnight. The labeled A-b1-42 peptide was centrifuged through 3K centrifugal filters twice and a 100K centrifugal filter once, and the final mixture was collected for further research.
Microglial phagocytosis assay
Twenty-four hours before microglial phagocytosis assay, we replaced microglial cultural medium with serum-free medium supplemented with 0.5 mM FLfA-b42. Cells were incubated with FLfA-b42 at 37°C for 4 h. After washing with cold PBS, the cells were fixed with 4% cold paraformaldehyde at 4°C for 10 min. Microglia were labeled with the Iba1 primary antibody (1:300, 019-19741; Wako) and the Alexa Fluor 633-labeled secondary antibody (1:500, A-21071; Thermo Fisher Scientific). Thirty cells were selected randomly for photo capture, and images were obtained using the Olympus FV1000 confocal laser scanning microscope and processed using ImageJ software.
Adeno-associated viral infection
The Cx3cr1-cre adeno-associated virus (AAV) [pAAV-CX3CR1-bGlobin-Flex-EGFP-Cre, 1.72 3 10 13 genome copies (GC)/ml], control AAV for Cx3cr1-cre AAV (2.07 3 10 13 GC/ml), Trem2 overexpression (OE) AAV (pAAV-EF1a-DIO-Trem2-IRES-EGFP, 1.81 3 10 13 GC/ml), and control AAV for Trem2 OE AAV (1.69 3 10 13 GC/ml), with a serotype of AAV2/8, were purchased from Obio Technology (Shanghai, China). Mice were anesthetized with ketamine and fixed on a stereotactic frame (RWD Life Science, Shenzhen, China). The skin over the skull was incised, and a small hole was made in the skull above the target using a microdrill (Hamilton, Bonaduz, Switzerland). The stereotactic coordinates were as follows [2 stereotactic coordinates per region (cortex and hippocampus) per cerebral hemisphere]: first, anteroposterior (AP), 22.00 mm; mediolateral (ML), 61.6 mm; After that, we calculated the vGlut1 puncta in cortex and hippocampus in 8-and 12-mo-old mice (APP/PS1 mice and APP/PS1-Trem2 KO mice, scale bars, 40 mm). D-G) Moreover, the synaptic structure of CA1 pyramidal neuron was also investigated by calculating the dendritic spine density and percentage of each spine type in the primary and secondary dendrites at 8 mo old [scale bar, 10 mm; (D, E )] and 12 mo old (F, G); n = 18-22/group for electrophysiological assay; n = 30 from 6/group for immunofluorescence and Golgi assay. Data are presented as means 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001 compared with APP/PS1 mice. dorsoventral (DV), 20.5 mm and AP, 23.00 mm; ML, 62.6 mm; DV, 21.0 mm from the bregma for injection into the cortex; and second, AP, 22.00 mm; ML, 61.6 mm; DV, 22.0 mm and AP, 23.00 mm; ML, 62.6 mm, and DV, 23.2 mm from the bregma for injection into the hippocampus. Animals were injected with 0.5 ml at each stereotactic coordinate of the appropriate AAV. The vector was injected at a rate of 0.1 ml/min, and the needle was left in place for 5 min prior to removal.
Multiplexed phospho-protein and cytokine signaling analysis
To investigate inflammatory related cytokine expression in isolated microglia (without culture), we collected microglia lysis, measured total protein concentration (Nanodrop 2000, Thermo Fisher, USA), and eventually detected using the Milliplex MAP Kit (Milli-poreSigma) according to the manufacturer's instructions.
Statistical analysis
Data are presented as the means 6 SEM. One-way ANOVA with Tukey's post hoc test was used to assess the differences among groups. Two-way repeated-measures ANOVA with Bonferroni post hoc analysis was used for the MWM test. A 2-tailed, unpaired Student's t test was used for comparisons between 2 groups. Values of P , 0.05 were accepted as significant. All statistical analyses were performed using Prism (v.5.01; GraphPad Software, La Jolla, CA, USA).
RESULTS
Trem2 deficiency ameliorates synaptic deficit early but exacerbates it late during AD pathogenesis
In recent studies, TREM2 has been well documented in regulating AD pathogenesis via mediating microglial response (13) (14) (15) , whereas Trem2 deletion inducing pathologic discrepancy (22, 23) between early and late stages is still elusive. Here, we generated APP/PS1-background Trem2-deletion mice by crossing Trem2 KO mice with APP/PS1 mice (Supplemental Fig. S1A ) and further confirmed the deletion efficiency of Trem2 in Trem2 fl/fl , APP/ PS1, and APP/PS1-Trem2 KO mice by PCR and WB analysis, which showed a significant decrement in APP/ PS1-Trem2 KO mice. After that, the LTP of hippocampal CA3-CA1 projections was evaluated at each pathologic stage (including 4, 8, 10, and 12 mo, Fig. 1A) . Surprisingly, the excitatory postsynaptic potential level (fEPSPs at 55-60 min after LTP induction were selected for analyses) was significantly up-regulated at 8 mo old [early-middle pathologic stage; fEPSPs were potentiated to 117 6 14% for APP/PS1 mice (n = 20), 144 6 12% for APP/PS1-Trem2 KO mice (n = 21)], whereas it was reduced at 12 mo old [middle-late pathologic stage; fEPSPs were potentiated to 125 6 12% for APP/PS1 mice (n = 20), 107 6 12% for APP/ PS1-Trem2 KO mice (n = 22)]. No significance was observed at 4 mo old [fEPSPs were potentiated to 146 6 11% for APP/PS1 mice (n = 18), 145 6 11% for APP/PS1-Trem2 KO mice (n = 20)] and 10 mo old [fEPSPs were potentiated to 125 6 11% for APP/PS1 mice (n = 21), 123 6 11% for APP/PS1-Trem2 KO mice (n = 22)] after Trem2 deletion in APP/PS1 mice. The number of synapses formed and the neurotransmitter traffic receptors' expression on the synaptic membrane are 2 major aspects of LTP mediation. In line with the electrophysiological results, APP/ PS1-TREM2 KO mice performed better at 8 mo old, whereas they lost their direction suddenly at 12 mo old in the MWM test compared with APP/PS1 mice (Supplemental Fig. S2A-H) . Therefore, we detected the number of synaptic puncta (Fig. 1B, C) and protein expression of synaptophysin and PSD95 ( Fig. 2A, B) in 8-and 12-mo-old mice. In line with LTP induction, vGlut1-positive synaptic puncta in both cortex and hippocampus and protein level of synaptophysin and PSD95 in hippocampus were ) . B, C ) After that, we calculated the vGlut1 puncta in cortex and hippocampus in 8-mo-old mice (scale bar, 40 mm). D, E ) The protein levels of synaptophysin and PSD95 were detected in hippocampus of 8-mo-old mice. F, G) Furthermore, the synaptic structure of CA1 pyramidal neuron [scale bar, 10 mm; (F )] was also investigated by calculating the (continued on next page) elevated for 8-mo-old but down-regulated for 12-mo-old APP/PS1-Trem2 KO mice compared with APP/PS1 mice. Furthermore, we also found a significant increase of dendritic spine density in primary dendrite (not secondary dendrite) of 8-mo-old APP/PS1-Trem2 KO mice (Fig.  1D , E) but a marked decrease of dendritic spine density in primary and secondary dendrite of 12-mo-old APP/ PS1-Trem2 KO mice (Fig. 1F, G) compared with agematched APP/PS1 mice. No significant change in spine shape among these mice was observed ( Fig. 1D-G) .
Combined with the results that protein levels of presynaptic vesicle releasing-related mediators (such as syntaxin, synaptosome-associated protein 25, mammalian uncoordinated-18, and rab interacting molecule; Fig.  2C -E) and postsynaptic neurotransmitter transferringassociated regulators (including GluA1, GluA2, GluN2A, and GluN2B; Fig. 2F-H) were not significantly altered when comparing APP/PS1-Trem2 KO mice with APP/ PS1 mice (at 8 and 12 mo old). This makes us think that Trem2 loss may ameliorate synaptic deficit early but exacerbate it late via regulating synaptic loss.
Trem2 loss reduces microglial phagocytosis against amyloid plaques and synapses
To test the hypothesis proposed, we further investigated the amyloidosis progression in the hippocampus of the AD model in this study. Because of the important role of microglial TREM2 on amyloid plaque accumulation (in a disease progression-dependent manner) reported by Wang et al. (28) , here, we found that microglial activation (total Iba1-positive cell number and Iba1-positive cell number per plaque) and amyloid plaque accumulation (amyloid plaque number and amyloid plaque area) were not significantly altered, at least before 8 mo old (Fig. 3A,  B) , but the amyloid plaque area was significantly increased in cortex and hippocampus at 12 mo old ( Fig.  3C -E) after Trem2 KO in APP/PS1 mice (whereas Iba1-positive cell number per plaque was significantly reduced). As we all know, the amyloid accumulation resulted from the imbalance of amyloid producing and amyloid clearance (29) . Interestingly, despite a significant increase of the protein level of carboxy-terminal fragmentb and concentration of A-b40 and A-b42 at 12 mo old (no significant alteration was observed at 8 mo old, Supplemental Fig. S3A-C) ; after Trem2 loss, amyloidogenic process of amyloid precursor protein (detected by the protein expression of beta-secretase 1 and PS1 loop and activity of aand g-secretase) was not changed between Trem2-sufficient and Trem2-deficient APP/PS1 mice, even at 12 mo old (Supplemental Fig. S3D-F) . Therefore, we separated hippocampal microglia (Supplemental Fig.   S4A ) from APP/PS1 (Supplemental Fig. S4B, C) and APP/ PS1-Trem2 KO mice (Supplemental Fig. S4D, E) , evaluated microglial phagocytic capacity by phagocytosis assay, and detected the activity of cathepsin B and cathepsin D. The data revealed that the fluorescent intensity of FLfA-b42 per cell (Supplemental Fig. S4F-H) , FLfA-b42 uptake ratio (Supplemental Fig. S4F-H) , and cathepsin (cathepsin B and cathepsin D) activity (Supplemental Fig. S4I ) in microglia were dramatically depressed after Trem2 deletion in APP/PS1 mice at both 8 and 12 mo old. Taking these data together, we speculated that Trem2 deficiency in the early pathologic stage promotes synaptic function via inhibiting microglial phagocytosis against synapse, whereas Trem2 loss in the late pathologic stage depressed microglial phagocytosis against synapse and amyloid plaque, which eventually led to more severe amyloid deposition inducing synaptic impairment.
Microglial Trem2 knockdown during the early-middle stage of AD progression improves synaptic function
In the CNS, TREM is mainly expressed in microglia (11) . Therefore, we next assessed how TREM2 contributes to AD pathogenesis during early-middle stage by expressing Cx3cr1-Cre in the cortex and hippocampus of APP/PS1-Trem2 fl/fl mice (Supplemental Fig. S5A ). We confirmed that TREM2 expression was dramatically suppressed from 4 to 8 mo old after Cx3cr1-cre AAV stereotactic microinjection (more than 70% inhibition rate, Supplemental Fig.  S5B, C) . A sharp reduction of TREM2 expression in isolated hippocampal microglia in Cx3cr1-AAV-injected APP/PS1 mice compared with control AAV-injected APP/PS1 mice further confirmed the AAV transduction in the long term (Supplemental Fig. S5D) . Surprisingly, we noticed that LTP of CA3-CA1 circuits were promoted at 8 mo old (fEPSPs were potentiated to 144 6 10% for APP/ PS1-Trem2 fl/fl mice receiving control AAV injection and 124 6 11% for APP/PS1-Trem2 fl/fl mice receiving Cx3cr1-AAV injection at 55-60 min after LTP induction, Fig. 4A ) in Trem2-deficient APP/PS1 mice when compared with APP/PS1 mice injected with control AAV. Unlike amyloidosis (no significant alteration was observed, Supplemental Fig. S5E-I) , the number of vGlut1positive synaptic puncta in cortex and hippocampus (Fig.  4B, C) and expression of synaptophysin and PSD95 (Fig.  4D, E) were notably up-regulated in the hippocampus of APP/PS1 mice that experienced Trem2 deletion during the early-middle pathologic stage. Despite a similar level of spine type, Trem2 loss at the early stage increased dendritic spine density (Fig. 4F, G) . As expected, the separated microglial (Supplemental Fig. S6A, B) was significantly reduced at 8 mo old [marked reduction of fluorescent intensity of FLfA-b42 per cell (Supplemental Fig. S6C, D) , FLfA-b42 uptake ratio (Supplemental Fig.  S6C, D) , and cathepsin (cathepsin B and cathepsin D) activity (Supplemental Fig. S6E )] after Trem2 deletion. A significant decrement of microglial CD68 expression in brain slice (Supplemental Fig. S6F ) and CD33 and LAMP1 expression ( Supplemental Fig. S6G, H) in isolated hippocampal microglia (without culture) was observed. Furthermore, inflammation-related cytokine expression in microglia detected by Milliplex Multiplex Assays showed that anti-inflammatory modulators (such as IL-4 and TGF-b2) were up-regulated (without significance), whereas proinflammatory regulators (such as IL-6 and NF-kB) were significantly reduced (Supplemental Fig. S6I ). Additionally, we also evaluated cognitive function by performing MWM test, which demonstrated that deletion of Trem2 during the early-middle stage of AD development reduced at d 6 and 7 (Fig. 4H, I) the latency to find the platform (d 1-7 ) and increased the time spent in the target quadrant (d 8, Fig. 4J , K) in 12-mo-old APP/PS1 mice with a similar swimming speed (Fig. 4I) . These data suggest that microglial Trem2 deficiency in APP/PS1 mice during the early-middle stage significantly reduced microglial responses (phagocytic capacity and anti-inflammatory activity) and improved synaptic function without altering amyloidosis at this initial pathologic stage.
Microglial Trem2 knockdown during the middle-late stage of AD progression exacerbates synaptic dysfunction
In the late stage of AD pathogenesis, amyloid accumulation will complicate the outcome of microglial TREM2-induced synaptic protection. Therefore, we established a middle-late pathologic microglial Trem2 knockdown mouse model via stereotactic injection of Cx3cr1-cre AAV in the cortex and hippocampus of APP/ PS1-Trem2 fl/fl mice at 6, 8, and 10 mo old (Supplemental Fig. S7A ). After confirming the AAV infection efficiency by WB in brain tissues (more than 70% inhibition rate, Supplemental Fig. S7B , C) and isolated microglia (Supplemental Fig. S7D ), a significant reduction of fEPSP slope was observed in 12-mo-old APP/PS1-Trem2 fl/fl mice after Cx3cr1-cre AAV injection during the middle-late pathologic stage (fEPSPs were potentiated to 126 6 11% for APP/PS1-Trem2 fl/fl mice receiving control AAV injection (n = 21), 106 6 11% for APP/PS1-Trem2 fl/fl mice receiving Cx3cr1-AAV injection (n = 22), Fig. 5A ). In line with this, the number of presynaptic puncta (cortex and hippocampus, Fig. 5B, C) , protein expression of synaptophysin and PSD95 (Fig. 5D, E) , and the dendritic spine density (Fig. 5F,  G) were significantly increased, though the spine type was not altered. On the contrary, amyloid deposition (Supplemental Fig. S7E, F) was notably increased but not the total Iba1-positive cell number, Iba1-positive cell number per plaque, and amyloid plaque number, which resulted from the up-regulation of amyloid production, such as a higher level of carboxy-terminal fragment-b (Supplemental Fig. S7G, H) , A-b40 ( Supplemental Fig. S7I ), and A-b42 (Supplemental Fig. S7I ) after Trem2 knockdown in the middle-late stage of AD. Furthermore, the MWM test suggest that cognitive impairment was accelerated (the latency to find platform was significantly increased at d 6 and 7, and time spent in the platform quadrant was decreased at d 8 with a similar swimming speed) by Trem2 knockdown (Fig.  5H-K) . Combined with the evidence that the phagocytic ability of isolated microglia (Supplemental Fig. S8A, B) were dramatically reduced [reduction of fluorescent intensity of FLfA-b42 per cell, FLfA-b42 uptake ratio, and cathepsin (cathepsin B and cathepsin D, Supplemental Fig. S8C-E ) activity] in the Trem2 middle-late stage knockdown APP/PS1 mice, we further speculated that microglial Trem2 knockdown in the late stage of AD pathogenesis depressed microglial phagocytosis toward synaptic element (protective role) and amyloid plaque (destructive role), whereas up-regulated amyloid deposition-induced neuronal toxicity occupied the leading positing and covered up the protective role.
Synaptic function was markedly impaired by microglial Trem2 overexpression in WT mice
To test whether TREM2 expressed in microglia triggers synaptic loss and induces synaptic dysfunction, we stereotactically injected Trem2-DIO (double-floxed inverse ORF) AAV in the cortex and hippocampus of Cx3cr1-cre mice at the age of 2, 4, and 6 mo, respectively (Supplemental Fig. S9A ). Under the situation of microglial Trem2 overexpression [up-regulated in brain tissues (more than 3 times during the 4-mo-old compared with 8-mo-old mice, Supplemental Fig. S9B ) and isolated hippocampal microglia (Supplemental Fig. S9C-E) ], the phagocytic function of separated microglia was significantly up-regulated (increase of fluorescent intensity of FLfA-b42 per cell, FLfA-b42 uptake ratio, and cathepsin (cathepsin B and cathepsin D, Supplemental Fig. S9F-H) activity. Moreover, microglial CD68 expression in brain slice (Supplemental Fig. S9I ) and CD33 and LAMP1 expression ( Supplemental Fig. S9J, K) in isolated hippocampal microglia (without culture) were notably up-regulated. Furthermore, inflammation-related cytokine expression in microglia detection by Milliplex multiplex assays showed that anti-inflammatory modulators (such as IL-4 and TGF-b2) were up-regulated, whereas proinflammatory regulators (such as IL-6) were significantly reduced assessed by the MWM test including the swimming path (H ), mean speed, and latency (I ) to find platform during the visible platform test and hidden platform test and the swimming path (J ) and time spent in each quadrant (K ) during the transfer test. Con, APP/PS1-Trem2 fl/fl mice with control AAV stereotactic injection (6-10 mo); Cre, APP/PS1-Trem2 fl/fl mice with Cx3cr1-cre AAV stereotactic injection (6-10 mo); n = 20-23/group for electrophysiological assay; n = 6/group for immunofluorescence and WB assay; n = 16/group for the MWM test. LaQ, left adjacent quadrant; OQ, opposite quadrant; PQ, platform quadrant; RaQ, right adjacent quadrant; Data are presented as means 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001 compared with Con mice. ) . B, C ) After that, we calculated the vGlut1 puncta in cortex and hippocampus in 8-mo-old mice (scale bar, 40 mm). D, E ) The protein levels of synaptophysin and PSD95 were detected in hippocampus of 8-mo-old mice. F, G) Furthermore, the synaptic structure of CA1 pyramidal neuron was also investigated by calculating the dendritic spine density and percentage of each spine type in the primary [scale bar, 10 mm;
(continued on next page) (Supplemental Fig. S9L ). Additionally, fEPSP slope in the CA3-CA1 circuit was notably reduced [fEPSPs were potentiated to 136 6 15% for APP/PS1-Trem2 fl/fl mice receiving control AAV injection (n = 23), 116 6 14% for APP/ PS1-Trem2 fl/fl mice receiving Cx3cr1-AAV injection (n = 24), Fig. 6A ] at 12 mo old compared with age-matched control AAV-injected mice. Moreover, the number of presynaptic puncta (cortex and hippocampus, Fig. 6B , C) and expression of synaptophysin and PSD95 (Fig. 6D, E) were observed to be significantly up-regulated after microglial Trem2 overexpression compared with WT mice. Additionally, the dendritic spine densities in primary and secondary dendrites were also found to be markedly decreased in microglial Trem2-overexpressing mice (Fig. 6F, G) , but spine type was not changed. Interestingly, overexpressed microglial Trem2 during 4-8 mo old significantly increased the latency to find the platform at d 6 and 7 in the hidden platform test (Fig. 6H, I) , whereas time spent in the target quadrant at d 8 in the probe trail test (Fig. 6J, K) was reduced, with a similar swimming speed, during the MWM test. Taking these data together, we believe that microglial TREM2 upregulation (even at a young age) in the CNS could dramatically up-regulate microglial responses (phagocytic capacity and anti-inflammatory activity) and induce catastrophic consequences by triggering synaptic loss.
Microglial TREM2 up-regulation reduces synaptic glutamatergic transmission but does not alter presynaptic release
To further confirm the role of microglial TREM2 on synaptic function, we performed patch-clamp analyses in the interneuron of CA3 in microglial Trem2 knockdown APP/PS1 mice and microglial Trem2-overexpressing WT mice. First, we injected Cx3cr1-cre AAV into the hippocampus of APP/PS1-Trem2 fl/fl mice during the earlymiddle stage of AD pathologic period and detected sEPSC and mEPSC at 8 mo old (Fig. 7A) . The data suggest that frequency of sEPSC was significantly up-regulated after Trem2 knockdown in APP/PS1 mice ( Fig. 7B, C) , whereas amplitude of sEPSC and amplitude and frequency of mEPSC were not significantly changed ( Fig. 7B-E) . These data indicate that microglial Trem2 down-regulation during the early-middle AD stage improved synaptic plasticity through reducing presynaptic vesicle releasing probability but not altered quantal size, which is in line with the observation of synaptic loss. Therefore, we tested whether Trem2 overexpression in microglia impairs presynaptic vesicle releasing probability (Fig. 7F ). As expected, frequency of sEPSC was notably decreased after Trem2 overexpression in microglia in WT mice ( Fig. 7G, H) , but no significant alteration was observed in amplitude of sEPSC and amplitude and frequency of mEPSC ( Fig. 7G-J) . Therefore, we concluded that microglial Trem2 up-regulation during early AD pathogenesis induces microglial phagocytosis toward synapses and reduces synaptic density, impairing cognitive function.
DISCUSSION
Previous research has suggested that TREM2 induces microglial clustering around A-b plaques and promotes A-b clearance (12, 15, 16) , and Trem2 deletion significantly reduces microglial phagocytosis and aggregation of microglia around plaques in a disease-dependent manner (12, 21, 25, 30, 31) ; interestingly, we also found a biphasic role of microglial TREM2 on amyloid pathology in APP/ PS1 mouse brain between the early and late stage of pathologic development. In the initial pathologic stage, TREM2 activation in microglia has no effect on amyloid accumulation, whereas in the late pathologic stage, induced microglial recruitment, engulfment, and phagocytosis responses against amyloid plaques were observed, despite a difference in the initial time point mainly due to the different genotype background of mice used [5XFAD (5 familial AD mutations) mice were used before, which exerts notable plaque deposition at 4 mo old, whereas APP/PS1 mice were used currently, in which relevant amyloid plaque deposition occurs since 8 mo old and gets worse at 12 mo old]. Additionally, based on current results, no differences between APP/PSI and APP/PSI-TREM2 KO in amyloid accumulation after 8 mo could be interpreted from 2 aspects. First, TREM2 deficiency has no effect on initial amyloidosis; for instance, the level of A-b (A-b40 and A-b42) and the activity of secretases (a-and gsecretase) were not altered, which has also been confirmed by a previous study (28) in 5XFAD mice showing that no significant difference of A-b accumulation was observed between TREM2-deficient and -sufficient 5XFAD mice at an early time point (4 mo old). Second, TREM2-induced microglial recruitment and phagocytic response against amyloid plaque was triggered by amyloid deposition, which allowed microglia to enclose amyloid plaque, alter plaque structure (more dense, less diffuse), and reduce neurite damage (28) . However, whether TREM2 induced microglial phagocytic synaptic loss is still not clear. The present study revealed that microglial TREM2 induced microglial phagocytic capacity since the early AD pathologic stage. This damaged the structure and function of synapses and, consequently, the learning and memory abilities of mice. These results indicate that TREM2-induced microglial (F )] and secondary dendrites [scale bar, 10 mm; (G)]. H-K) Then, cognitive function was assessed by the MWM test including the swimming path (H ), mean speed, and latency (I ) to find platform during the visible platform test and hidden platform test and the swimming path (J ) and time spent in each quadrant (K ) during the transfer test. Con, Cx3cr1-cre mice with control AAV stereotactic injection (2-6 mo); OE, Cx3cr1-cre mice with Trem2-DIO AAV stereotactic injection (2-6 mo); n = 6/group for immunofluorescence and WB assay, n = 16/group for the MWM test. LaQ, left adjacent quadrant; OQ, opposite quadrant; PQ, platform quadrant; RaQ, right adjacent quadrant; Data are presented as means 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001 compared with Con mice.
response is a very early event and contributes to the early synaptic dysfunction, which reminds us of its diagnostic potential, due to the limitation of detecting cerebrospinal fluid A-b40, A-b42, T-tau, and P-tau on predicting the preclinical stage of AD (32) . Although no statistically significant difference of soluble (s)TREM2 levels between healthy controls and patients with AD (33) was observed after diagnosis, accumulating evidence supports the perspective of considering key mediators on regulating microglial response [including sTREM2 (34, 35) , APOE (36), and TAR DNA-binding protein 43 (37, 38) ] and molecular debris from injured synapse [such as a-synuclein (39), synaptic vesicle glycoprotein 2A (40) , and neurogranin (41)] as biomarkers for AD diagnosis during the preclinical stage. In agreement, we noticed a significant improvement of synaptic function after Trem2 knockdown during the early stage of AD progression, whereas there was a notable synaptic loss post-Trem2 overexpression, even for WT mice. Having said that, innate microglial response takes a great part in early synaptic dysfunction (42, 43) . Regarding synaptic function, Trem2 deletion improved signaling transduction along the neural pathway and up-regulated the levels of presynaptic and postsynaptic structure-related proteins, including PSD95 and synaptophysin, but not those of the GluA or GluN. The rodent AD model described herein demonstrated that Trem2 deletion prevented synaptic loss (without altering synaptic properties such as spine shape and neurotransmission process), which helped ameliorate cognitive abilities. To go a further step, detecting the much earlier key modulators that trigger innate microglial responses and regulating these processes to predict and prevent AD pathologic development from the preclinical stage may be a more reasonable choice, but AD is a complex process involving multiple factors, such as A-b accumulation and synaptic involvement, which may synergize or interact to promote AD development. The mechanisms of such interactions among these factors require further investigation.
In this study, we also observed a double-edged effect of TREM2-induced microglial phagocytosis in AD development. It induces microglial clustering around A-b plaques and promotes A-b clearance (12, 44) while mediating the synaptic loss and neurodegeneration. The former (A-b clearance promotion) attenuates, but the latter (synaptic loss induction) inhibits, the pathologic progression of AD (45) (46) (47) . Interestingly, Trem2 deficiency depressed microglial phagocytosis toward synapse, and reduced synaptic loss eventually promoted cognitive function during the early-middle pathologic stage of AD; however, Trem2 inhibition depressed microglial phagocytosis, which resulted in a significant increase of amyloid plaque deposition and dramatically impairs synaptic function. Combined with the previous observation that Trem2 deficiency exerted a notable discrepancy on regulating amyloid plaque formation between early and late pathologic progression, for instance, Trem2 deficiency displays a significant depressive or no effect on the amyloid pathology during the early-middle stage (21, 23, 28, 30) but exerts a dramatic promotion on amyloid plaque formation at the late stage (21, 23, 28) , this suggests that the outcomes resulting from TREM2-induced microglial phagocytic capacity toward synapse and amyloid plaque are depended on disease progression. In brief, during the early-middle pathologic stage, TREM2-enhancing microglial phagocytosis mainly induces synaptic loss to serve a negative role; however, time greatly changes the pathologic situation when amyloid deposition occupies the leading positing at the middle-late pathologic stage and Trem2-upregulating microglial phagocytosis gradually supports a positive role. This disease progression-dependent role of TREM2 highlights its potential as a diagnostic parameter and therapeutic target. However, the exact mechanism by which TREM2 regulates synaptic function via microglia remains unknown. We believe that TREM2-induced microglial activity, including direct interaction (48-50), Figure 8 . TREM2 up-regulation promotes microglial phagocytosis equally against synapse and amyloid plaques and eventually results in different outcomes. During the early-middle pathologic stage, TREM2 enhancing microglial phagocytosis mainly causes synaptic loss. However, TREM2 up-regulating microglial phagocytosis gradually supports a positive role when amyloid deposition occupies the leading position at the middle-late pathologic stage.
inflammatory regulation (21, 51) , and gliotransmitter release (52, 53) , is involved.
In summary, the present study revealed that TREM2induced innate microglial response, which leads to indifferent phagocytosis toward synapse and amyloid plaque, may be a crucial step in AD development (Fig. 8) .
The down-regulation of Trem2 during the early stage of AD progression successfully protected synaptic function and ameliorated AD symptoms, including synaptic dysfunction and cognitive decline, whereas down-regulation of Trem2 during the late stage of AD progression impaired synaptic plasticity which mainly results from the shape rise of amyloid deposition. These results provide evidence on revealing the complex role of TREM2 in AD progression and highlight that TREM2 induced innate microglial response is a potential AD target for early diagnosis and intervention.
